BIOPHARM INTERNATIONAL

Scope & Guideline

Advancing the Frontiers of Biopharmaceutical Research

Introduction

Welcome to the BIOPHARM INTERNATIONAL information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of BIOPHARM INTERNATIONAL, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1542-166x
PublisherADVANSTAR COMMUNICATIONS INC
Support Open AccessNo
CountryUnited States
TypeTrade Journal
Convergefrom 2002 to 2024
AbbreviationBIOPHARM INT / Biopharm. Int.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address131 W 1ST STREET, DULUTH, MN 55802

Aims and Scopes

BIOPHARM INTERNATIONAL focuses on the latest advancements and challenges in the biopharmaceutical industry, emphasizing the intersection of innovative technologies and regulatory compliance. The journal caters to a diverse audience, including researchers, industry professionals, and regulatory bodies, providing insights into biopharmaceutical manufacturing, quality control, and therapeutic development.
  1. Biopharmaceutical Manufacturing:
    The journal explores various aspects of biopharmaceutical manufacturing processes, including upstream and downstream processing, automation, and the use of single-use technologies, highlighting innovations that enhance efficiency and product quality.
  2. Regulatory Compliance and Quality Assurance:
    Articles frequently address the importance of adhering to regulatory standards and good manufacturing practices (GMP), with a focus on how these regulations impact drug development, approval processes, and manufacturing operations.
  3. Innovations in Drug Delivery and Therapeutics:
    The journal covers emerging technologies in drug delivery systems, including mRNA therapeutics, gene therapies, and novel biologics, emphasizing their potential to transform treatment paradigms.
  4. Bioanalytical Methods and Quality Control:
    There is a strong focus on bioanalytical methods for quality control and assurance in biopharmaceuticals, with insights into the latest technologies and methodologies to ensure safety and efficacy.
  5. Market Trends and Economic Considerations:
    The journal also examines market dynamics, economic factors affecting drug pricing, and trends in biopharmaceutical investment, providing a comprehensive view of the industry's landscape.
Recent publications within BIOPHARM INTERNATIONAL highlight several emerging themes that reflect current trends and innovations in the biopharmaceutical sector. These themes indicate where research and industry focus is likely to grow in the coming years.
  1. Advanced Therapeutics and Gene Editing:
    The increasing prevalence of articles discussing gene therapies, CRISPR technologies, and other advanced therapeutics reflects a significant trend towards innovative treatment modalities that promise personalized medicine solutions.
  2. Digital Transformation and Automation:
    A strong emphasis on digitalization and automation in biopharmaceutical manufacturing processes is evident, showcasing the industry's move towards Industry 4.0 concepts that enhance efficiency and data integrity.
  3. Sustainability and Green Practices:
    Emerging discussions around sustainability practices in biopharma manufacturing, including waste reduction and environmentally friendly processes, indicate a growing commitment to responsible production.
  4. Patient-Centric Approaches in Drug Development:
    There is a trend towards incorporating patient perspectives and real-world evidence in drug development, emphasizing the importance of patient engagement in clinical trials and therapeutic outcomes.
  5. Supply Chain Resilience and Security:
    Recent articles highlight the need for robust supply chain strategies to mitigate risks, particularly in light of challenges posed by global events like the COVID-19 pandemic, indicating a renewed focus on supply chain management.

Declining or Waning

As the biopharmaceutical landscape evolves, certain themes have shown a decline in prominence within the journal's publications. This may reflect shifts in industry focus, advancements in technology, or changing regulatory environments.
  1. Traditional Small-Molecule Drug Development:
    There appears to be a waning focus on traditional small-molecule drug development, as the industry increasingly shifts towards biologics, gene therapies, and advanced therapeutics that offer novel treatment options.
  2. Static Quality Control Practices:
    Static quality control methodologies are being replaced by more dynamic and integrated quality assurance practices, leading to a decrease in articles focused solely on traditional quality control approaches.
  3. Conventional Clinical Trial Designs:
    There is a noticeable decline in content related to conventional clinical trial methodologies, as adaptive and innovative trial designs gain traction in response to the need for more efficient drug development processes.

Similar Journals

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Shaping the Future of Pharmaceutical Practices and Education.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Innovating drug delivery for a healthier tomorrow.
Publisher: ELSEVIERISSN: 0939-6411Frequency: 9 issues/year

European Journal of Pharmaceutics and Biopharmaceutics is a leading academic journal published by Elsevier, dedicated to advancing the field of pharmaceutical sciences through high-quality research. Established in 1991, this multidisciplinary journal offers a platform for the dissemination of innovative findings in pharmaceutics and biopharmaceutics, covering crucial aspects such as drug formulation, delivery systems, and the interface of pharmaceutical formulation with biological systems. The journal is well-regarded for its impact, earning a Q1 status in Pharmaceutical Science and consistent Q2 rankings in both Biotechnology and Medicine (Miscellaneous) categories in 2023, thereby highlighting its significance in the scientific community. With an impressive Scopus ranking of 26th percentile in Pharmaceutical Science and 60th percentile in Biotechnology, it positions itself firmly at the forefront of research, supporting researchers, professionals, and students in their quest to address complex health challenges. While the journal does not offer an open-access option, it facilitates a rigorous peer-review process, ensuring that published articles meet the highest standards of scientific integrity. For those looking to make meaningful contributions to the field, the European Journal of Pharmaceutics and Biopharmaceutics serves as an essential resource and reference point.

Pharmaceutical Medicine

Advancing the frontiers of pharmacological research.
Publisher: SPRINGER INT PUBL AGISSN: 1178-2595Frequency: 6 issues/year

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.

CURRENT PHARMACEUTICAL DESIGN

Pioneering Insights in Pharmacology and Drug Development
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Journal of Pharmaceutical Investigation

Connecting researchers to shape the future of therapeutics.
Publisher: SPRINGERNATUREISSN: 2093-5552Frequency: 6 issues/year

Journal of Pharmaceutical Investigation, published by SPRINGERNATURE, is a leading academic resource in the field of pharmaceutical sciences, offering critical insights and innovative research findings. With an impact factor that underscores its significance, this journal ranks in the Q1 category for both Pharmacology and Pharmaceutical Science as of 2023, showcasing its high-quality publications and rigorous peer-review processes. Operating from the Netherlands, the journal spans from 2012 to 2024, offering a rich archive of interdisciplinary research contributions that advance knowledge in pharmacology, toxicology, and pharmaceutics. It holds impressive Scopus rankings, placing it among the top-tier journals in its categories, which enhances its appeal to researchers, professionals, and students aiming to publish their work or stay up-to-date with the latest advancements in the pharmaceutical field. Engaging with the Journal of Pharmaceutical Investigation not only enriches your understanding but also connects you with a community dedicated to advancing healthcare and therapeutic innovations.

Future Journal of Pharmaceutical Sciences

Pioneering Discoveries in Drug Development and Therapeutics
Publisher: SPRINGERISSN: 2314-7245Frequency: 1 issue/year

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

AAPS PHARMSCITECH

Bridging Science and Technology in Pharmaceutical Research
Publisher: SPRINGERISSN: 1530-9932Frequency: 1 issue/year

AAPS PHARMSCITECH is a prestigious peer-reviewed journal published by Springer, focusing on the dynamic field of pharmaceutical sciences and technology. With an ISSN of 1530-9932, it provides a vital platform for disseminating cutting-edge research that spans key areas including drug discovery, pharmacology, toxicology, and ecological impacts of pharmaceuticals. The journal is recognized for its rigorous scientific contributions, currently holding a commendable Q2 quartile ranking across several relevant categories, including Agronomy and Crop Science, Aquatic Science, and Medicine in 2023. Notably, it ranks 43rd out of 183 in the Scopus Pharmacology, Toxicology, and Pharmaceutics category, placing it in the 76th percentile of its field. Aiming to foster innovation and collaboration among researchers, professionals, and students, AAPS PHARMSCITECH is committed to advancing scientific knowledge and addressing contemporary challenges in pharmaceutical sciences. The journal offers various access options to ensure wide dissemination of research findings, making it an essential resource for those dedicated to enhancing public health through pharmaceutical advancements.

Turkish Journal of Pharmaceutical Sciences

Shaping the Future of Healthcare Through Research
Publisher: GALENOS PUBL HOUSEISSN: 1304-530XFrequency: 6 issues/year

The Turkish Journal of Pharmaceutical Sciences, an esteemed publication by GALENOS PUBL HOUSE, has been a prominent platform for research and innovation in the fields of Pharmaceutical Sciences and Molecular Medicine since its inception as an Open Access journal in 2004. Based in Turkey, this journal serves as a vital resource for researchers, professionals, and students keen on exploring the latest advancements in drug development, pharmacology, and therapeutic innovations. With an ISSN of 1304-530X and an E-ISSN of 2148-6247, the journal is indexed in leading databases and has demonstrated strong rankings in the Scopus index, notably securing the second quartile in Pharmaceutical Sciences. Furthermore, it fosters academic collaboration and knowledge dissemination by making its content freely accessible. The journal aims to inspire groundbreaking research, providing an important academic forum for the dissemination of valuable insights that impact the pharmaceutical sector and contribute to global health.

BIOLOGICALS

Advancing the frontiers of biological research.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1045-1056Frequency: 6 issues/year

BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

International Journal of Pharmaceutics-X

Advancing pharmaceutical innovation for a global impact.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.